Humiras is so critical to AbbVie's earnings though you will very...

Humiras is so critical to AbbVie's earnings though you will very rarely find a company where their lead drug is more than 20% or earnings let alone more than 50% - it was really the lead that Abbott Lab's was able to spin off AV in the split. Humiras composition of matter goes off patent in the next few years but it still shouldn't really effect them it's not easy for generic companies to copy antibodies - well yet anyway. Still if in time they can show BN006 works the same if not better without the side effects & ease of oral administration than Humira it's hard to see them not protecting such an important asset. Still need to see clinic but PoC already is key.

With $4.5M MC, no debt, <260M shares on issue and enough cash to see them into 2015

It's an easy bottom draw with the potential for black swan out of left field & currently no inflated values.